Emergent BioSolutions, a US-based global life sciences company, has a 20-year track record of providing the US government and its allies with critically needed medical countermeasures to protect their military and civilian populations from serious public health threats. The company develops and manufactures vaccines and therapeutics for biological weapons such as anthrax, smallpox, and botulism, as well as devices to address exposure to chemical warfare agents. Its development programs include product candidates for emerging infectious diseases (EID) like Zika, Ebola, Nipah, and pandemic influenza.

“This year is a special year for the company as we approach our 20th year in operations,” said Daniel J. Abdun-Nabi, CEO of Emergent BioSolutions. “Our history of growth began in Lansing, Michigan, USA with one site, one product – our anthrax vaccine, and approximately 180 employees.”